144 related articles for article (PubMed ID: 33408299)
1. Reduction of fatty liver in rats by nicotinamide via the regeneration of the methionine cycle and the inhibition of aldehyde oxidase.
Yokouchi C; Nishimura Y; Goto H; Sato M; Hidoh Y; Takeuchi K; Ishii Y
J Toxicol Sci; 2021; 46(1):31-42. PubMed ID: 33408299
[TBL] [Abstract][Full Text] [Related]
2. Alleviation of fatty liver in a rat model by enhancing N
Takeuchi K; Yokouchi C; Goto H; Umehara K; Yamada H; Ishii Y
Biochem Biophys Res Commun; 2018 Dec; 507(1-4):203-210. PubMed ID: 30446221
[TBL] [Abstract][Full Text] [Related]
3. Nicotinamide prevents sweet beverage-induced hepatic steatosis in rats by regulating the G6PD, NADPH/NADP
Mejía SÁ; Gutman LAB; Camarillo CO; Navarro RM; Becerra MCS; Santana LD; Cruz M; Pérez EH; Flores MD
Eur J Pharmacol; 2018 Jan; 818():499-507. PubMed ID: 29069580
[TBL] [Abstract][Full Text] [Related]
4. Pharmacological doses of nicotinic acid and nicotinamide are independently metabolized in rats.
Shibata K; Fukuwatari T; Suzuki C
J Nutr Sci Vitaminol (Tokyo); 2014; 60(2):86-93. PubMed ID: 24975217
[TBL] [Abstract][Full Text] [Related]
5. High fructose-containing drinking water-induced steatohepatitis in rats is prevented by the nicotinamide-mediated modulation of redox homeostasis and NADPH-producing enzymes.
Loza-Medrano SS; Baiza-Gutman LA; Manuel-Apolinar L; García-Macedo R; Damasio-Santana L; Martínez-Mar OA; Sánchez-Becerra MC; Cruz-López M; Ibáñez-Hernández MA; Díaz-Flores M
Mol Biol Rep; 2020 Jan; 47(1):337-351. PubMed ID: 31650383
[TBL] [Abstract][Full Text] [Related]
6. Fatty liver and fibrosis in glycine N-methyltransferase knockout mice is prevented by nicotinamide.
Varela-Rey M; Martínez-López N; Fernández-Ramos D; Embade N; Calvisi DF; Woodhoo A; Rodríguez J; Fraga MF; Julve J; Rodríguez-Millán E; Frades I; Torres L; Luka Z; Wagner C; Esteller M; Lu SC; Martínez-Chantar ML; Mato JM
Hepatology; 2010 Jul; 52(1):105-14. PubMed ID: 20578266
[TBL] [Abstract][Full Text] [Related]
7. Hepatic content of S-adenosylmethionine, S-adenosylhomocysteine and glutathione in rats receiving treatments modulating methyl donor availability.
Henning SM; McKee RW; Swendseid ME
J Nutr; 1989 Oct; 119(10):1478-82. PubMed ID: 2531221
[TBL] [Abstract][Full Text] [Related]
8. Comparison of metabolic fates of nicotinamide, NAD+ and NADH administered orally and intraperitoneally; characterization of oral NADH.
Kimura N; Fukuwatari T; Sasaki R; Shibata K
J Nutr Sci Vitaminol (Tokyo); 2006 Apr; 52(2):142-8. PubMed ID: 16802695
[TBL] [Abstract][Full Text] [Related]
9. Nicotinamide overload may play a role in the development of type 2 diabetes.
Zhou SS; Li D; Sun WP; Guo M; Lun YZ; Zhou YM; Xiao FC; Jing LX; Sun SX; Zhang LB; Luo N; Bian FN; Zou W; Dong LB; Zhao ZG; Li SF; Gong XJ; Yu ZG; Sun CB; Zheng CL; Jiang DJ; Li ZN
World J Gastroenterol; 2009 Dec; 15(45):5674-84. PubMed ID: 19960564
[TBL] [Abstract][Full Text] [Related]
10. Dietary betaine promotes generation of hepatic S-adenosylmethionine and protects the liver from ethanol-induced fatty infiltration.
Barak AJ; Beckenhauer HC; Junnila M; Tuma DJ
Alcohol Clin Exp Res; 1993 Jun; 17(3):552-5. PubMed ID: 8333583
[TBL] [Abstract][Full Text] [Related]
11. Fate of nicotinamide differs due to an intake of nicotinamide.
Shibata K; Shimada H; Taguchi H
Biosci Biotechnol Biochem; 1996 Jul; 60(7):1204-6. PubMed ID: 8782418
[TBL] [Abstract][Full Text] [Related]
12. MicroRNA-122 Inhibits Lipid Droplet Formation and Hepatic Triglyceride Accumulation via Yin Yang 1.
Wu GY; Rui C; Chen JQ; Sho E; Zhan SS; Yuan XW; Ding YT
Cell Physiol Biochem; 2017; 44(4):1651-1664. PubMed ID: 29216638
[TBL] [Abstract][Full Text] [Related]
13. A PPAR Pan Agonist, MHY2013 Alleviates Age-Related Hepatic Lipid Accumulation by Promoting Fatty Acid Oxidation and Suppressing Inflammation.
An HJ; Lee B; Kim SM; Kim DH; Chung KW; Ha SG; Park KC; Park YJ; Kim SJ; Yun HY; Chun P; Yu BP; Moon HR; Chung HY
Biol Pharm Bull; 2018; 41(1):29-35. PubMed ID: 29311481
[TBL] [Abstract][Full Text] [Related]
14. Dietary egg white protein hydrolysate improves orotic acid-induced fatty liver in rats by promoting hepatic phospholipid synthesis and microsomal triglyceride transfer protein expression.
Jiang Z; Kimura Y; Shirouchi B; Tanaka Y; Tsai WT; Yuan X; Sato M
J Nutr Biochem; 2021 Dec; 98():108820. PubMed ID: 34273531
[TBL] [Abstract][Full Text] [Related]
15. Effects of Nonalcoholic Fatty Liver Disease on Hepatic CYP2B1 and in Vivo Bupropion Disposition in Rats Fed a High-Fat or Methionine/Choline-Deficient Diet.
Cho SJ; Kim SB; Cho HJ; Chong S; Chung SJ; Kang IM; Lee JI; Yoon IS; Kim DD
J Agric Food Chem; 2016 Jul; 64(27):5598-606. PubMed ID: 27321734
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of betaine-homocysteine S-methyltransferase in rats causes hyperhomocysteinemia and reduces liver cystathionine β-synthase activity and methylation capacity.
Strakova J; Gupta S; Kruger WD; Dilger RN; Tryon K; Li L; Garrow TA
Nutr Res; 2011 Jul; 31(7):563-71. PubMed ID: 21840473
[TBL] [Abstract][Full Text] [Related]
17. S-Adenosylmethionine increases circulating very-low density lipoprotein clearance in non-alcoholic fatty liver disease.
Martínez-Uña M; Varela-Rey M; Mestre D; Fernández-Ares L; Fresnedo O; Fernandez-Ramos D; Gutiérrez-de Juan V; Martin-Guerrero I; García-Orad A; Luka Z; Wagner C; Lu SC; García-Monzón C; Finnell RH; Aurrekoetxea I; Buqué X; Martínez-Chantar ML; Mato JM; Aspichueta P
J Hepatol; 2015 Mar; 62(3):673-81. PubMed ID: 25457203
[TBL] [Abstract][Full Text] [Related]
18. S-Adenosylmethionine: From the Discovery of Its Inhibition of Tumorigenesis to Its Use as a Therapeutic Agent.
Pascale RM; Simile MM; Calvisi DF; Feo CF; Feo F
Cells; 2022 Jan; 11(3):. PubMed ID: 35159219
[TBL] [Abstract][Full Text] [Related]
19. NNMT activation can contribute to the development of fatty liver disease by modulating the NAD
Komatsu M; Kanda T; Urai H; Kurokochi A; Kitahama R; Shigaki S; Ono T; Yukioka H; Hasegawa K; Tokuyama H; Kawabe H; Wakino S; Itoh H
Sci Rep; 2018 Jun; 8(1):8637. PubMed ID: 29872122
[TBL] [Abstract][Full Text] [Related]
20. Icariin Alleviates Nonalcoholic Fatty Liver Disease in Polycystic Ovary Syndrome by Improving Liver Fatty Acid Oxidation and Inhibiting Lipid Accumulation.
Hai Y; Zuo L; Wang M; Zhang R; Wang M; Ren L; Yang C; Wang J
Molecules; 2023 Jan; 28(2):. PubMed ID: 36677577
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
